Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Cushing’s Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019Cushing’s Syndrome Therapeutics Market Forecast to Display High Growth until 2019
By: Rajesh Gunnam Japan, Spain, The UK and The US) was worth $45.2m in 2011, after increasing at a Compound Annual Growth Rate (CAGR) of 6.2% during 2006-2011. The market is expected to witness a CAGR of 9.1% from 2011-2019, to be worth $90.8m by 2019. The current treatment options available for Cushing’s syndrome consist of surgery, radiation therapy and drug therapy, or a combination of these. There is no Food and Drug Administration (FDA) approved drug available in the Cushing’s syndrome therapeutics market and market is completely dominated by off-label drugs (drugs that are not approved by any regulatory agency for the indication). Drug therapy is not considered the first line of treatment option for Cushing’s syndrome. The drug therapy is considered a second or third-line treatment option. The drug therapies are primarily prescribed in relapse cases of Cushing’s syndrome or those patients who are not suitable for the surgery. Sometimes, drug therapy and radiation therapy combined together for the effective management of Cushing’s syndrome. The growth witnessed in the Cushing’s syndrome therapeutics market during the historical period of 2006-2011, was due to increasing awareness among patients and physicians. These factors have further increased the diagnosis rate in the Cushing’s syndrome therapeutics market. The Cushing’s syndrome therapeutics market is expected to show high growth during the forecast period of 2011-2019, due to the expected launch of late stage (field and Phase III molecules) pipeline molecules. The expected launch of Korlym (mifepristone) GlobalData’s analysis indicates that Cushing’s syndrome therapeutics market has significant unmet need exists in drug treated Cushing’s syndrome patients. The major unmet need exists in Cushing’s syndrome therapeutics market are a lack of FDA approved drugs and off-label drug usage causing several adverse effects such as severe hepatotoxicity, rash, gynecomastia, excessive sedation and hirsutism (excessive hairiness). One of the major unmet needs in Cushing’s syndrome therapeutics market is that the currently used off-label drugs do not affect the size of the tumor. The currently used drugs only provide symptomatic relief to patients. Although, these drugs significantly reduce the cortisol levels in Cushing’s syndrome patients. Another unmet need exists in terms of diagnosis. Cushing’s syndrome patients are often misdiagnosed due to its rarity and low awareness among physicians and due to its symptoms overlapping with other diseases’. These significant unmet needs can be addressed by the expected launch of Korlym, pasireotide and Mifedren, with their improved safety and efficacy profiles compared to the existing off-label drugs used in the Cushing’s syndrome therapeutics market. Overall, the Cushing’s syndrome therapeutics market is not well-served by the off-label drugs currently available. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ GlobalData, the industry analysis specialist, has released its new report, “Cushing's Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Cushing's Syndrome Therapeutics market. The report identifies the key trends shaping and driving the global Cushing's Syndrome Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Cushing's Syndrome Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number